Corbus Pharmaceuticals Holdings, Inc. (CRBP) ended last trading session with a change of 5.77 percent. It trades at an average volume of 1.87M shares versus 1.38M shares recorded at the end of last trading session. The share price of $8.25 is at a distance of 716.83 percent from its 52-week low and down -23.47 percent versus its peak. The company has a market cap of $366.63M and currently has 44.44M shares outstanding. The share price is currently 26.32 percent versus its SMA20, 14.36 percent versus its SMA50, and 114.15 percent versus its SMA200. The stock has a weekly performance of 18.71 percent and is 400 percent year-to-date as of the recent close.
On November 14, 2016 Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced positive topline results from its Phase 2 study evaluating Resunab (“JBT-101”) for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). JBT-101 out-performed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo. The higher the CRISS score the greater the improvement; a CRISS score ≥ 20% (CRISS20) can be considered a medically meaningful improvement. The difference in CRISS scores between JBT-101 and placebo groups over the trial period was significant (p = 0.044). Differences in categorical levels of CRISS responses and changes from baseline in the five individual domains of the CRISS score also supported clinical benefit of JBT-101.
PhaseRx, Inc. (PZRX) recently recorded 149.56 percent change and currently at $2.82 is 26757.14 percent away from its 52-week low and down -51.11 percent versus its peak. It has a past 5-day performance of 135 percent and trades at an average volume of 49.70K shares. The stock has a 1-month performance of 85.51 percent and is -44.71 percent year-to-date as of the recent close. There were about 11.72M shares outstanding which made its market cap $33.05M. The share price is currently 154.48 percent versus its SMA20, 60.2 percent versus its SMA50, and -10.02 percent versus its SMA200.
On Nov. 28, 2016 PhaseRx, Inc. (PZRX) announced that its lead candidate, PRX-OTC, which is being developed for the treatment of ornithine transcarbamylase deficiency (OTCD), has received orphan drug designation by the U.S. Food and Drug Administration (FDA).
OTCD is a rare liver disorder caused by an inherited single-gene deficiency that results in hyperammonemia (elevated ammonia in the blood), and can lead to irreversible neurological impairment, coma and death. PRX-OTC is an intracellular enzyme replacement therapy (i-ERT) designed to replace the missing or defective enzyme in patients with OTCD, thereby correcting the disease. PRX-OTC has shown therapeutic potential in a preclinical model of OTCD, including lowering of blood ammonia and survival of 100% of treated mice.